Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.96 |
| ▸ | PRKCI | P41743 | 1/20 | 0.96 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalazinone SCHEMBL51553 | 0.98 | PARP1 (1.00) | PARP1HSD17B10TDP1ALDH1A1PRKCI | |
| Phthalazinone SCHEMBL11516875 | 0.96 | PARP1 (0.96) | PARP1HSD17B10TDP1ALDH1A1PRKCI | |
| Phthalazinone SCHEMBL11516881 | 0.96 | PARP1 (0.96) | PARP1HSD17B10TDP1ALDH1A1PRKCI | |
| Phthalazinone SCHEMBL11519239 | 0.96 | PARP1 (0.96) | PARP1HSD17B10TDP1ALDH1A1PRKCI | |
| Phthalazinone SCHEMBL9617397 | 0.96 | PARP1 (0.96) | PARP1HSD17B10TDP1ALDH1A1PRKCI | |
| Phthalazinone SCHEMBL11519244 | 0.96 | PARP1 (0.96) | PARP1HSD17B10TDP1ALDH1A1PRKCI | |
| Phthalazinone SCHEMBL11690359 | 0.96 | PARP1 (0.96) | PARP1HSD17B10TDP1ALDH1A1PRKCI | |
| Phthalazinone SCHEMBL4663241 | 0.96 | PARP1 (0.96) | PARP1HSD17B10TDP1ALDH1A1PRKCI | |
| Phthalazinone SCHEMBL2962226 | 0.96 | PARP1 (0.96) | PARP1HSD17B10TDP1ALDH1A1PRKCI | |
| Phthalazinone SCHEMBL28416004 | 0.96 | PARP1 (0.96) | PARP1HSD17B10TDP1ALDH1A1PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025227505-A1 | HALOGEN-FREE FLAME-RETARDANT POLYURETHANE ELASTOMER AND PREPARATION PROCESS THEREFOR | 上海皆利新材料科技有限公司 | 2025-11-06 | — | — | WO | disclosed |
| US-20240327375-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | ADDEX PHARMA S.A. (CH) | 2024-10-03 | — | — | US | disclosed |
| CN-118108924-B | Halogen-free flame-retardant polyurethane elastomer and preparation process thereof | 上海皆利新材料科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118108924-A | Halogen-free flame-retardant polyurethane elastomer and preparation process thereof | 上海皆利新材料科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4337643-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | Addex Pharma S.A (CH) | 2024-03-20 | — | — | EP | disclosed |
| CN-117597331-A | Substituted heterobicyclic derivatives as MGLU7 receptor negative allosteric modulators | 阿德克斯法尔马股份公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-2824098-A1 | Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Kudos Pharmaceuticals Limited (GB) | 2015-01-14 | — | — | EP | disclosed |
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-05-16 | — | — | US | disclosed |
| US-8247416-B2 | Phthalazinone derivative | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-08-21 | — | — | US | disclosed |
| US-8168635-B2 | 2-(aminomethyl)-5-phenyltetrahydrofuran; 4-(3,4-Dimethoxyphenyl)-2-[5-(2-{5-[2-(5-fluoro-2-methoxyphenyl)-ethyl]-tetrahydrofuran-2-yl}-ethylamino)-pentyl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one; dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2374800-A2 | Methods for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Kudos Pharmaceuticals Limited (GB) | 2011-10-12 | — | — | EP | disclosed |
| US-7692006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-2064189-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | Kudos Pharmaceuticals Limited (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-10-23 | — | — | US | disclosed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| EP-1771435-A4 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RES INST (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1771435-A2 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | Human Biomolecular Research Institute (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006025920-A2 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | GAP43, SLC18A2, CHRNA6 | PARP1 4366/4885HSD17B10 3739/4885TDP1 1124/4885 |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | PARP1, PARP11, PARP2 | PARP1 1/4885HSD17B10 1956/4885TDP1 122/4885 |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | PML, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA4 | PARP1 379/4885HSD17B10 859/4885TDP1 3822/4885 |
| US-20240327375-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | GRM7, GRM2, GRM1 | PARP1 4246/4885HSD17B10 3270/4885TDP1 2268/4885 |
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | GAP43, SLC18A2, CHRNA6 | PARP1 4366/4885HSD17B10 3739/4885TDP1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.